Burt Adelman
Founder chez VERVE THERAPEUTICS, INC.
Fortune : 6 M $ au 31/03/2024
Profil
Burt A.
Adelman is the founder of Verve Therapeutics, Inc. (founded in 2018) and holds the title of Chairman.
He is also the founder of Clear Creek Bio, Inc. Dr. Adelman's current jobs include Director of the New England Division at the American Cancer Society, Inc., Overseers Director at Tufts University School of Medicine, and Senior Advisor at Novo Ventures 1 A.
His former jobs include Chairman at Carrick Therapeutics Ltd.
(2017-2018), Director at Progenics Pharmaceuticals, Inc., Director at Achillion Pharmaceuticals, Inc., Director at TetraLogic Pharmaceuticals Corp., Independent Director at Astria Therapeutics, Inc. (2016-2021), Director at New England Healthcare Institute, Director at NeuroHealing Pharmaceuticals, Inc., Director at Sirona Medical Technologies, Inc. (2015-2021), Director at Syntimmune, Inc. (2016-2018), Executive Vice President of Portfolio Strategy at Biogen MA, Inc., Executive Vice President of Portfolio Strategy at Biogen, Inc. (1991-2007), Chief Medical Officer and EVP of Research & Development at Dyax Corp.
(2012-2016), Executive Vice President of Development at BioGenetic Technologies, Inc., and Executive Vice President at Biogen Idec New Ventures, Inc. (1991-2008).
He also served as President of Research & Development at Sesen Bio, Inc. (2010-2011) and as an Associate at The Brigham & Women's Hospital, Inc. Dr. Adelman's education includes an undergraduate degree from Trinity College (Connecticut) and a doctorate from Weill Cornell Medical College.
Dr. Adelman is also the founder of Clear Creek Bio, Inc...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERVE THERAPEUTICS, INC.
0,55% | 18/09/2023 | 428 326 ( 0,55% ) | 6 M $ | 31/03/2024 |
Postes actifs de Burt Adelman
| Sociétés | Poste | Début |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Founder | 01/01/2018 |
| Tufts University School of Medicine | Corporate Officer/Principal | - |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Founder | - |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Corporate Officer/Principal | - |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Corporate Officer/Principal | - |
Anciens postes connus de Burt Adelman
| Sociétés | Poste | Fin |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Director/Board Member | 28/01/2021 |
Sirona Medical Technologies, Inc.
 Sirona Medical Technologies, Inc. Medical/Nursing ServicesHealth Services Sirona Medical Technologies, Inc. develops a cardiac mapping and ablation catheter used for the treatment of atrial fibrillation. The company is headquartered in Windsor, CT. | Director/Board Member | 01/01/2021 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Director/Board Member | 01/11/2018 |
Carrick Therapeutics Ltd.
 Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Chairman | 10/10/2018 |
| ░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Burt Adelman
| Trinity College (Connecticut) | Undergraduate Degree |
| Weill Cornell Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
| BioGenetic Technologies, Inc. | Process Industries |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
American Cancer Society, Inc.
American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Commercial Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
New England Healthcare Institute
 New England Healthcare Institute Miscellaneous Commercial ServicesCommercial Services New England Healthcare Institute operates as a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. The company was founded by Henri A. Termeer in 2002 and is headquartered in Boston, MA. | Commercial Services |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
NeuroHealing Pharmaceuticals, Inc.
 NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Carrick Therapeutics Ltd.
Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Health Technology |
Sirona Medical Technologies, Inc.
Sirona Medical Technologies, Inc. Medical/Nursing ServicesHealth Services Sirona Medical Technologies, Inc. develops a cardiac mapping and ablation catheter used for the treatment of atrial fibrillation. The company is headquartered in Windsor, CT. | Health Services |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Health Technology |
